You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(9.28)︱ 吉利汽車科創板上市申請獲批; 宏基資本擬溢價五成要約回購21.36%股份
格隆匯 09-28 23:10

【科創板】

吉利汽車(00175.HK):科創板首發過會

【財務數據】

中國高精密(00591.HK)全年淨虧擴大至8794萬元

PALADIN(00495.HK)年度淨虧擴大至1.29億港元

全民國際(08170.HK)年度扭虧為盈至1165萬港元

寶聯控股(08201.HK)年度由盈轉虧3580萬港元

盈健醫療(01419.HK)年度由盈轉虧4040萬港元

森美控股(00756.HK)年度扭虧為盈至3.15億元

【業績預告】

新加坡美食控股(08496.HK)預計年度由盈轉虧260萬新加坡元

卓能(集團)(00131.HK)預計年度溢利將大幅減少

【復牌停牌】

宏基資本(02288.HK)擬溢價51.11%要約回購21.36%股份 明日復牌

【增減持】

漢港控股(01663.HK)獲主席汪林冰增持36.4萬股

【股權變更】

山東墨龍(00568.HK)控股股東將公司29.53%表決權全部委託至壽光金鑫

【併購出售】

協合新能源(00182.HK)擬5.76億元出售電廠權益 取得收益5340萬元

九江銀行(06190.HK)擬9.5億元轉讓不良債權資產

【重大事項】

中國抗體-B(03681.HK):SM03報告摘要獲接納在APLAR虛擬大會上作現場口頭陳述

長城汽車(02333.HK)擬對長城濱銀增資45億元

新天綠色能源(00956.HK)向豐寧抽蓄公司增資3.1億元

上海醫藥(02607.HK):左炔諾孕酮片通過仿製藥一致性評價

東陽光藥(01558.HK):治療精神分裂症產品奧氮平片獲批准上市

富力地產(02777.HK): H股全流通完成 轉換H股29日起上市

麗珠醫藥(01513.HK): 苯磺酸氨氯地平膠囊通過仿製藥質量和療效一致性評價

常茂生物(00954.HK)簽訂關閉搬遷協議 搬遷補償合計2.05億元

沛然環保(08320.HK)攜手新城市建設發展成立合營 打造綠色、智能及健康社區

華住集團-S(01179.HK)逐一回應博尼塔斯報告指控,稱其實屬毫無依據

君實生物(01877.HK)JUPITER-02研究達到預設的主要研究終點

昊海生物科技(06826.HK):在研產品"人工晶狀體"啟動臨牀試驗

巨濤海洋石油服務(03303.HK)擬溢價三成配售不超1.5億份認購權證

【回購註銷】

合生創展集團(00754.HK)9月28日耗資1999.1萬港元回購115.4萬股

金鷹商貿集團(03308.HK)9月28日耗資607.61萬港元回購86.6萬股

中國旺旺(00151.HK)9月28日耗資733.88萬港元回購138.1萬股

網龍(00777.HK)9月28日耗資325.44萬港元回購20萬股

爪哇控股(00251.HK)9月28日耗資278.03萬港元回購29萬股

康臣藥業(01681.HK)9月28日耗資166.95萬港元回購50萬股

雷蛇(01337.HK)9月28日耗資145.14萬港元回購88.4萬股

友誼時光(06820.HK)9月28日耗資352.50萬港元回購149萬股

華檢醫療(01931.HK)9月28日耗資236.5萬港元回購100萬股

富智康集團(02038.HK)9月28日耗資182.17萬港元回購175.4萬股

【股權激勵】

碧桂園服務(06098.HK)授出合共7150萬份購股權

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account